JP2009544630A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009544630A5 JP2009544630A5 JP2009521075A JP2009521075A JP2009544630A5 JP 2009544630 A5 JP2009544630 A5 JP 2009544630A5 JP 2009521075 A JP2009521075 A JP 2009521075A JP 2009521075 A JP2009521075 A JP 2009521075A JP 2009544630 A5 JP2009544630 A5 JP 2009544630A5
- Authority
- JP
- Japan
- Prior art keywords
- insulin
- concentration
- value range
- biomarker
- tissue kallikrein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 23
- 102000004877 Insulin Human genes 0.000 claims 11
- 108090001061 Insulin Proteins 0.000 claims 11
- 229940125396 insulin Drugs 0.000 claims 11
- 239000000090 biomarker Substances 0.000 claims 10
- 101710176219 Kallikrein-1 Proteins 0.000 claims 8
- 102000057032 Tissue Kallikreins Human genes 0.000 claims 8
- 208000030159 metabolic disease Diseases 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 claims 4
- 102100040918 Pro-glucagon Human genes 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 claims 4
- 229940123993 Incretin mimetic Drugs 0.000 claims 3
- 239000000674 adrenergic antagonist Substances 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 3
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 claims 3
- 239000000859 incretin Substances 0.000 claims 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 3
- 108010011459 Exenatide Proteins 0.000 claims 2
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 claims 2
- 108010088406 Glucagon-Like Peptides Chemical class 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 102000010631 Kininogens Human genes 0.000 claims 2
- 108010077861 Kininogens Proteins 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229960001519 exenatide Drugs 0.000 claims 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 claims 1
- IOHPVZBSOKLVMN-UHFFFAOYSA-N 2-(2-phenylethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1CCC1=CC=CC=C1 IOHPVZBSOKLVMN-UHFFFAOYSA-N 0.000 claims 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- 102000003914 Cholinesterases Human genes 0.000 claims 1
- 108090000322 Cholinesterases Proteins 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- 108010024636 Glutathione Proteins 0.000 claims 1
- 102000002261 High-Molecular-Weight Kininogen Human genes 0.000 claims 1
- 108010000487 High-Molecular-Weight Kininogen Proteins 0.000 claims 1
- 101000605522 Homo sapiens Kallikrein-1 Proteins 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 1
- 208000001280 Prediabetic State Diseases 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 229940123464 Thiazolidinedione Drugs 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 claims 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 claims 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 claims 1
- 229940048961 cholinesterase Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000004153 glucose metabolism Effects 0.000 claims 1
- 229960003180 glutathione Drugs 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 239000004026 insulin derivative Substances 0.000 claims 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82037906P | 2006-07-26 | 2006-07-26 | |
| US90982907P | 2007-04-03 | 2007-04-03 | |
| PCT/CA2007/001321 WO2008011713A1 (en) | 2006-07-26 | 2007-07-26 | Methods of diagnosis and treatment for metabolic disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013058106A Division JP2013129672A (ja) | 2006-07-26 | 2013-03-21 | 代謝障害の診断及び治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009544630A JP2009544630A (ja) | 2009-12-17 |
| JP2009544630A5 true JP2009544630A5 (https=) | 2010-05-27 |
Family
ID=38981091
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009521075A Pending JP2009544630A (ja) | 2006-07-26 | 2007-07-26 | 代謝障害の診断及び治療方法 |
| JP2013058106A Pending JP2013129672A (ja) | 2006-07-26 | 2013-03-21 | 代謝障害の診断及び治療方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013058106A Pending JP2013129672A (ja) | 2006-07-26 | 2013-03-21 | 代謝障害の診断及び治療方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20100008899A1 (https=) |
| EP (1) | EP2051732A4 (https=) |
| JP (2) | JP2009544630A (https=) |
| CA (1) | CA2659012A1 (https=) |
| WO (1) | WO2008011713A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2153234A2 (en) * | 2007-05-11 | 2010-02-17 | The Institutes for Pharmaceutical Discovery, LLC | Methods for early diagnosis of kidney disease |
| EP2182978A4 (en) | 2007-07-20 | 2012-03-21 | Sanomune Inc | TISSUE KALLIKREIN FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID PROTEIN |
| WO2010009557A1 (en) * | 2008-07-25 | 2010-01-28 | Sanomune Inc. | Tissue kallikrein for the treatment of parkinson's disease |
| AU2010228068A1 (en) * | 2009-03-25 | 2011-10-20 | Diamedica Inc. | Tissue kallikrein for the treatment of pancreatic beta-cell dysfunction |
| US20140205578A1 (en) * | 2011-06-17 | 2014-07-24 | The John Hopkins University | Methods for increasing insulin sensitivity and treating diabetes |
| CN103424496B (zh) * | 2012-05-24 | 2015-02-18 | 山东绿叶制药有限公司 | 一种测定痕量艾塞那肽的方法 |
| US20130315891A1 (en) | 2012-05-25 | 2013-11-28 | Matthew Charles | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods |
| US20130323222A1 (en) * | 2012-06-04 | 2013-12-05 | Matthew Charles | Human tissue kallikrein 1 glycosylation isoforms |
| WO2014059536A1 (en) * | 2012-10-15 | 2014-04-24 | Diamedica Inc. | Combination of an insulin and tissue kallikrein 1 |
| CN103940935A (zh) * | 2013-01-23 | 2014-07-23 | 中国农业科学院兰州畜牧与兽药研究所 | 一种动物血浆中氢溴酸槟榔碱含量的测定方法 |
| WO2017066659A1 (en) * | 2015-10-16 | 2017-04-20 | The Trustees Of Columbia University In The City Of New York | Jag1 expression predicts therapeutic response in nash |
| AU2018230478B2 (en) | 2017-03-09 | 2025-01-23 | Diamedica Inc. | Dosage forms of tissue kallikrein 1 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2657382A1 (de) * | 1976-12-17 | 1978-06-29 | Thera Ges Fuer Patente | Orales antidiabetikmittel |
| DE2658984C2 (de) * | 1976-12-27 | 1983-08-18 | Thera Gesellschaft für Patentverwertung mbH, 8036 Herrsching | Injizierbare Insulinpräparate |
| US4474893A (en) * | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5403486A (en) * | 1991-12-31 | 1995-04-04 | Baker Hughes Incorporated | Accelerator system in a centrifuge |
| US6586438B2 (en) * | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
| US6355243B1 (en) * | 1999-11-13 | 2002-03-12 | Bayer Corporation | Method of thrombolysis by local delivery of active plasmin |
| DE10055742B4 (de) * | 2000-11-10 | 2006-05-11 | Schwarz Pharma Ag | Neue Polyester, Verfahren zu ihrer Herstellung und aus den Polyestern hergestellte Depot-Arzneiformen |
| US7195759B2 (en) * | 2001-06-06 | 2007-03-27 | The University Of Manitoba | Therapeutic uses of glandular kallikrein |
| US20030158090A1 (en) * | 2001-07-23 | 2003-08-21 | Ulrik Pedersen-Bjergaard | Renin-angiotensin system in diabetes mellitus |
-
2007
- 2007-07-26 CA CA002659012A patent/CA2659012A1/en not_active Abandoned
- 2007-07-26 US US12/374,872 patent/US20100008899A1/en not_active Abandoned
- 2007-07-26 WO PCT/CA2007/001321 patent/WO2008011713A1/en not_active Ceased
- 2007-07-26 JP JP2009521075A patent/JP2009544630A/ja active Pending
- 2007-07-26 EP EP07784988A patent/EP2051732A4/en not_active Withdrawn
-
2013
- 2013-03-21 JP JP2013058106A patent/JP2013129672A/ja active Pending
- 2013-03-26 US US13/850,968 patent/US20130280235A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009544630A5 (https=) | ||
| Wang et al. | Diabetes mellitus contributes to idiopathic pulmonary fibrosis: a review from clinical appearance to possible pathogenesis | |
| JP6199186B2 (ja) | ２型糖尿病の治療用の医薬の製造のためのａｖｅ００１０の使用 | |
| Kapitza et al. | Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin | |
| Tahrani et al. | Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus | |
| Raz et al. | Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus | |
| Montanya et al. | A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus | |
| Schweizer et al. | Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug‐naïve patients with Type 2 diabetes | |
| Taskinen et al. | Safety and efficacy of linagliptin as add‐on therapy to metformin in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled study | |
| EP1928499B1 (en) | Use of a dpp-iv inhibitor to reduce hypoglycemic events | |
| Scott et al. | Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes | |
| Pfützner et al. | Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks | |
| JP6442284B2 (ja) | ２型糖尿病の処置のためのリキシセナチド及びメトホルミン | |
| JP6410604B2 (ja) | ２型糖尿病における基礎インスリンに対する上乗せ療法としてのリキシセナチド | |
| JP6410600B2 (ja) | ２型糖尿病患者における低血糖症の予防 | |
| Paolisso et al. | Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks? | |
| JP6438944B2 (ja) | インスリングラルギン／リキシセナチド固定比率製剤 | |
| Aroor et al. | The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin | |
| CN120754229A (zh) | 使用gip/glp1共激动剂用于治疗的方法 | |
| Gong et al. | Site‐specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity | |
| EP1461070A2 (en) | Combined use of a glp-1 compound and a modulator of diabetic late complications | |
| JP2014514355A (ja) | ２型糖尿病患者の体重減少を誘導する際、または／および２型糖尿病患者の体重増加を防止するために使用するための組合せ医薬 | |
| CN103917241A (zh) | 用于2型糖尿病患者中的血糖控制的药物组合 | |
| US10653753B2 (en) | Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives | |
| Zander et al. | The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes |